Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Income from Continuing Operations: 2018-2024

Historic Income from Continuing Operations for Phathom Pharmaceuticals (PHAT) over the last 7 years, with Dec 2024 value amounting to -$334.3 million.

  • Phathom Pharmaceuticals' Income from Continuing Operations rose 64.98% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.4 million, marking a year-over-year increase of 19.14%. This contributed to the annual value of -$334.3 million for FY2024, which is 65.99% down from last year.
  • As of FY2024, Phathom Pharmaceuticals' Income from Continuing Operations stood at -$334.3 million, which was down 65.99% from -$201.4 million recorded in FY2023.
  • Phathom Pharmaceuticals' Income from Continuing Operations' 5-year high stood at -$129.2 million during FY2020, with a 5-year trough of -$334.3 million in FY2024.
  • Over the past 3 years, Phathom Pharmaceuticals' median Income from Continuing Operations value was -$201.4 million (recorded in 2023), while the average stood at -$244.4 million.
  • Data for Phathom Pharmaceuticals' Income from Continuing Operations shows a maximum YoY tumbled of 65.99% (in 2024) over the last 5 years.
  • Over the past 5 years, Phathom Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$129.2 million in 2020, then declined by 9.81% to -$141.8 million in 2021, then plummeted by 39.33% to -$197.6 million in 2022, then dropped by 1.92% to -$201.4 million in 2023, then slumped by 65.99% to -$334.3 million in 2024.